Abstract
Purpose
To report on the results of interferon-α 2a (IFNα) treatment in patients with Behçet uveitis unresponsive to conventional immunosuppressive therapy.
Methods
We retrospectively analyzed the medical records of 44 patients who had been treated with IFNα between September 2001 and May 2005. The initial dose of IFNα was 6 MU/day in 37 patients (84.1%) and 3 MU/day in 7 patients (15.9%), and was gradually tapered after ocular inflammation was suppressed. Immunosuppressive agents were discontinued. Oral corticosteroids were discontinued or maintained at a dosage of less than 10 mg prednisone equivalent per day. Main outcome measures were recurrence of posterior or panuveitis attacks and changes in visual acuity.
Results
Sixteen patients (36.4%) remained relapse free during treatment, whereas 28 (63.6%) patients had recurrent uveitis attacks. Four of these were considered treatment failures and were switched to other treatments. In the remaining 40 patients, the mean duration of treatment was 12.4±10.8 months (range 3–45 months). In 9 of 40 patients (22.5%) treatment could be discontinued 22.2±13.4 months after therapy, and 8 (20%) of these patients had sustained remission for up to 24 months. Three patients (7.5%) were switched to other therapies because of side effects. The frequency of uveitis attacks per 6 months was reduced from 1.6±1.2 to 0.8±0.9 in 26 patients who had a minimum follow-up of 6 months before and after IFNα therapy (p<0.05). There was a significant improvement in visual acuity and this was preserved throughout follow-up in 38 (95%) of 40 patients.
Conclusions
A partial or complete response was obtained with IFNα therapy in 91% of Turkish patients with Behçet uveitis refractory to conventional immunosuppressive treatment. Our results suggest that there may be differences in therapeutic efficacy and side-effect profile of IFNα in different patient populations. Comparative studies are needed to investigate this hypothesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Çalgüneri M, Öztürk MA, Ertenli I, Kiraz S, Apras S, Özbalkan Z (2003) Effects of interferon α treatment on the clinical course of refractory Behçet’s disease: an open study. Ann Rheum Dis 62:492–493
Hanley JP, Haydon GH (1998) The biology of interferon-alpha and the clinical significance of anti-interferon antibodies. Leukoc Lyphoma 29:257–268
International Study Group for Behçet’s Disease (1990) Evaluation of diagnostic (‘classification’) criteria in Behçet’s disease: toward internationally agreed criteria. Lancet 335:1078–1080
Kötter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Günaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HA, Srübiger N (2003) Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423–431
Kötter I, Günaydin I, Zierhut M, Stübiger N (2004) The use of interferon alfa in Behçet disease: review of the literature. Semin Arthritis Rheum 33:320–335
Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Altunbas HH, Urgancioglu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380
Wechsler B, Bodaghi B, Huong DL, Fardeau C, Amoura Z, Cassoux N, Piette JC, LeHoang P (2000) Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet’s disease. Ocul Immunol Inflamm 8:293–301
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tugal-Tutkun, I., Güney-Tefekli, E. & Urgancioglu, M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefe's Arch Clin Exp Ophthalmol 244, 1692–1695 (2006). https://doi.org/10.1007/s00417-006-0346-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-006-0346-y